VT104 (also known as VT3989), an allosteric TEAD inhibitor targeting the TEAD lipid pocket, demonstrated strong preclinical efficacy in models of KRAS-mutant cancers and is currently undergoing clinical evaluation [63]. The gene discussed is KRAS; the disease is cancer.